KUALA LUMPUR: Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialisation of antibody-based solutions for infectious diseases with pandemic potential, has announced new data from the company’s Covid-19 antibody programme.
Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300mg intramuscular (IM) dose given as a single injection being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept 29 – Oct 3.
In addition, Adagio’s chief scientific officer, Laura Walker, PhD, will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimisation of this differentiated antibody clinical candidate in an oral presentation at the 19th Annual Discovery on Target Conference on Sept 30.
“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralising and delivered as a single IM injection – could have on people with or at risk of Covid-19,” said Adagio chief medical officer, Lynn Connolly, MD, PhD in a statement.
“These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of Covid-19.
“We anticipate these data will support an Emergency Use Authorisation (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of Covid-19, the disease caused by SARS-CoV-2.
Advancing ADG20 through multiple clinical trials on a global basis, Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch.
For more information, visit www.adagiotx.com. – Bernama
